There is no single best route into Japan. The right model depends on the product, development stage, clinical evidence, regulatory pathway, reimbursement potential, resources and desired level of control. Options may include out-licensing, appointing a distributor, assigning a local designated marketing authorization holder (DMAH) or setting up a Japanese subsidiary. Many clinical-stage companies first assess partner-led models before investing in a full local organization.

Ideally, companies should include Japan when forming global clinical development plans. Early assessment can clarify whether global data may support a Japan strategy, whether local evidence may be needed, which regulatory pathway is feasible and what commercial model is realistic. Waiting until after US or European approval can reduce flexibility, increase overall costs and delay regulatory preparation, partner discussions and launch planning.

Japan should be considered as part of a global launch strategy when the product addresses meaningful unmet needs and has a feasible regulatory, reimbursement and commercial pathway. This may be particularly relevant for specialty medicines, advanced therapies, medical devices and diagnostics in the fields of oncology, neurodegenerative disease, autoimmune/inflammatory and other rare diseases. The decision should reflect the available evidence, local execution requirements, investment needed and the company’s broader Asia Pacific objectives.

Yes. A company can enter Japan after US or European approval, but late planning may create avoidable delays. The existing evidence package must still be assessed against Japanese regulatory and reimbursement requirements. Additional analysis, documentation or local evidence may be needed. Earlier planning can align data strategy, partner selection and launch readiness, but an approved product can still present a viable Japan opportunity.

Japan is often a good market for rare disease therapeutics with clear differentiation and solid clinical evidence. Companies should assess patient identification, diagnosis rates, specialist networks, clinical requirements, reimbursement potential and local treatment patterns. Because rare disease opportunities are highly product-specific, the Japan case should be evaluated on its own evidence and commercial practicalities rather than assumed from global market potential.

Before entering Japan, companies should evaluate unmet need, patient numbers, current standard-of-care, clinical evidence, regulatory requirements, reimbursement pricing potential, competition, partnering options and operational demands. The assessment should also test whether the required investment matches the company’s objectives and resources. Japan market entry is a combined clinical, regulatory and commercial decision, not simply an approval exercise.

Leaving Japan planning until later can limit clinical data options, delay regulatory work, weaken reimbursement preparation and reduce the range of potential partners. Key global decisions may already be fixed, making Japan harder or more expensive to include. Early evaluation does not require a commitment to enter the market. It preserves options and allows the company to make informed decisions as clinical and commercial evidence develops.